Stephen D. Shafran

2.5k total citations
15 papers, 537 citations indexed

About

Stephen D. Shafran is a scholar working on Epidemiology, Infectious Diseases and Hepatology. According to data from OpenAlex, Stephen D. Shafran has authored 15 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 7 papers in Infectious Diseases and 7 papers in Hepatology. Recurrent topics in Stephen D. Shafran's work include Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). Stephen D. Shafran is often cited by papers focused on Hepatitis C virus research (7 papers), Hepatitis B Virus Studies (6 papers) and HIV/AIDS drug development and treatment (5 papers). Stephen D. Shafran collaborates with scholars based in Canada, Australia and United Kingdom. Stephen D. Shafran's co-authors include Mitchell L. Shiffman, Karl Barange, Ricard Solà, Amy Lin, Stefan Zeuzem, Bruce R. Bacon, Hugh Harley, David R. Nelson, Fredy Suter and Brian Conway and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Stephen D. Shafran

14 papers receiving 522 citations

Peers

Countries citing papers authored by Stephen D. Shafran

Since Specialization

Citations

This map shows the geographic impact of Stephen D. Shafran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen D. Shafran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen D. Shafran more than expected).

Fields of papers citing papers by Stephen D. Shafran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen D. Shafran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen D. Shafran. The network helps show where Stephen D. Shafran may publish in the future.

Co-authorship network of co-authors of Stephen D. Shafran

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen D. Shafran. A scholar is included among the top collaborators of Stephen D. Shafran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen D. Shafran. Stephen D. Shafran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Tu1497 – Efficacy and Safety of Sofosbuvir/Velpatasvir for the Treatment of Patients with Chronic Hepatitis C Genotype 1-6 Infection: Integrated Analysis of Eight Phase 3 Clinical Trials 2019 ·Gastroenterology ·Eric Lawitz, Jordan J. Feld, Ira M. Jacobson, Ola Weiland, Ajit Sood, Stuart C. Gordon, Stephen D. Shafran, (unknown), (unknown), (unknown), (unknown), Gerald Crans, Hongmei Mo, Mark Sulkowski	1
2	Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III) 2017 ·Journal of Viral Hepatitis ·Stephen D. Shafran, Douglas W. Shaw, (unknown), Kosh Agarwal, Graham R. Foster, Manal Abunimeh, (unknown), (unknown), Bo Fu, Eric Cohen, Daniel E. Cohen, E. Gane	9
3	753 High SVR Rates With ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection 2016 ·Gastroenterology ·Andrew J. Muir, Simone I. Strasser, Stanley Wang, Stephen D. Shafran, Maurizio Bonacini, Paul Y. Kwo, David Wyles, Edward Gane, Sandra Lovell, Chih‐Wei Lin, Teresa I. Ng, Jens Kort, Federico Mensa	2
4	Su1063 Long Term Follow-Up of Patients Treated With Sofosbuvir in the Phase 3 Studies Fission, Positron, Fusion and Neutrino 2014 ·Gastroenterology ·Kimberly L. Beavers, Stephen D. Shafran, Hongmei Mo, John McNally, Diana M. Brainard, William T. Symonds, (unknown), Alessandra Mangia	2
5	Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3 2007 ·New England Journal of Medicine ·Mitchell L. Shiffman, Fredy Suter, Bruce R. Bacon, David R. Nelson, Hugh Harley, Ricard Solà, Stephen D. Shafran, Karl Barange, Amy Lin, (unknown), Stefan Zeuzem	384
6	Management of Chronic Hepatitis B: Consensus Guidelines 2007 ·Canadian Journal of Gastroenterology ·Morris Sherman, Stephen D. Shafran, Kelly W. Burak, Karen Doucette, Winnie Wong, Nigel Girgrah, Eric M. Yoshida, Eberhard L. Renner, Philip C. Wong, Marc Deschênes	18
7	Management of chronic hepatitis C: Consensus guidelines 2007 ·Canadian Journal of Gastroenterology ·Morris Sherman, Stephen D. Shafran, Kelly W. Burak, Karen Doucette, Winnie Wong, Nigel Girgrah, Eric M. Yoshida, Eberhard L. Renner, Philip C. Wong, Marc Deschênes	30
8	Infective endocarditis and perivalvular abscess: a dangerous duo. 2002 ·PubMed ·Stephen D. Shafran	4
9	Pharmacology and clinical experience with amprenavir 2000 ·Expert Opinion on Investigational Drugs ·Brian Conway, Stephen D. Shafran	12
10	Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial 1999 ·AIDS ·Joel Singer, Anona Thorne, Peter Phillips, Anita Rachlis, Mark Miller, M. John Gill, Fiona Smaill, Walter F. Schlech, Hélène Senay, Stephen D. Shafran	5
11	Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment of Mycobacterium avium Complex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin? 1998 ·Clinical Infectious Diseases ·Stephen D. Shafran, James Talbot, (unknown), (unknown), Joel Singer, Peter Phillips, Irving E. Salit, Sharon Walmsley, I. W. Fong, M. John Gill, Anita Rachlis, Richard Lalonde, (unknown)	16
12	Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals 1998 ·International Journal of Infectious Diseases ·Stephen D. Shafran	6
13	Topical Undecylenic Acid for Herpes Simplex Labialis: A Multicenter, Placebo‐Controlled Trial 1997 ·The Journal of Infectious Diseases ·Stephen D. Shafran, Stephen L. Sacks, Fred Y. Aoki, D. Lorne Tyrrell, Walter F. Schlech, Jack Mendelson, Donald Rosenthal, M. John Gill, (unknown), Ih Chang	21
14	Norfloxacin Is Inferior to Chloroquine for Falciparum Malaria in Northwestern Zambia: A Comparative Clinical Trial 1992 ·The Journal of Infectious Diseases ·(unknown), (unknown), Stephen D. Shafran	19
15	Branhamella catarrhalis bronchopulmonary isolates in PICU patients 1989 ·Pediatric Pulmonology ·(unknown), Stephen D. Shafran, (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact